Trupanion, Inc. — FY2022 Form 10-K Summary
Business context and reporting period
Trupanion provides medical insurance for cats and dogs in the United States, Canada, Europe, Puerto Rico, and Australia. Its two reporting segments are subscription business, consisting primarily of direct-to-consumer subscription fees, and other business, consisting largely of business-to-business underwriting, third-party programs, and software solutions. The filing covers the fiscal year ended December 31, 2022; the requested fourth-quarter period ended December 31, 2022 is also summarized where disclosed.
At December 31, 2022, total pets enrolled were 1,537,573, including 869,862 subscription pets. The company employed 1,187 people and was listed on Nasdaq under the symbol TRUP.
Financial and operating metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Total revenue | $905.2 million | $699.0 million | +29% |
| Subscription revenue | $596.6 million | $494.9 million | +21% |
| Other business revenue | $308.6 million | $204.1 million | +51% |
| Gross profit | $122.2 million | $104.3 million | +17% |
| Gross margin | 13.5% | 14.9% | Down 1.4 points |
| Operating loss | $43.0 million | $35.2 million | Loss widened |
| Net loss | $44.7 million | $35.5 million | Loss widened |
| Net loss per diluted share | $1.10 | $0.89 | Loss widened |
| Net cash from operating activities | $(8.0) million | $7.5 million | Declined |
Subscription revenue represented 66% of consolidated revenue, down from 71% in 2021. Subscription segment cost of revenue was 83% of segment revenue, producing an approximately 17% segment gross margin; the other business segment cost of revenue was 92% of revenue, producing an approximately 8% segment gross margin. Consolidated operating margin was approximately negative 4.8% and net margin was approximately negative 4.9%.
Veterinary invoice expense was $649.7 million, up from $486.1 million, reflecting enrollment growth and higher veterinary care costs and utilization. New pet acquisition expense increased 14% to $89.5 million. Technology and development expense increased 49% to $25.1 million, including investment in pre-revenue initiatives. Stock-based compensation expense totaled $33.4 million, compared with $28.2 million in 2021.
Key subscription metrics included monthly average revenue per pet of $63.82, average monthly retention of 98.69%, lifetime value per pet of $641, and average pet acquisition cost of $289. Subscription pets increased 24% year over year, while total pets enrolled increased 31%.
Fourth-quarter 2022 results
| Metric | Q4 2022 | Q4 2021 |
|---|---|---|
| Total revenue | $246.0 million | $194.4 million |
| Operating loss | $9.2 million | $5.8 million |
| Net loss | $9.3 million | $7.0 million |
| Subscription pets enrolled | 869,862 | 704,333 |
| Average monthly retention | 98.69% | 98.74% |
Q4 revenue grew approximately 27% year over year, but losses increased. Q4 subscription cost of revenue was 83% of subscription revenue, and total cost of revenue was approximately 86% of consolidated revenue.
Liquidity, cash flow, debt, and capital
- Cash and cash equivalents were $65.6 million, and short-term investments were $156.8 million, for total cash, cash equivalents, and short-term investments of $222.4 million at year-end.
- Net cash used in operating activities was $8.0 million, compared with $7.5 million provided in 2021. Management attributed the change primarily to increased pet acquisition spending and faster payment of veterinary invoices.
- Net cash used in investing activities was $67.5 million, including $15.0 million for acquisitions and $17.1 million for property and equipment.
- Net cash provided by financing activities was $60.7 million, primarily reflecting $69.1 million of net debt proceeds, partially offset by $5.8 million of share repurchases.
- Debt totaled $69.5 million at year-end under a $150.0 million credit facility. The facility bears floating-rate interest; the stated rate was approximately 9.7% at December 31, 2022. The company reported $75.0 million of remaining credit availability and compliance with all covenants.
- The credit facility is secured by substantially all company and subsidiary assets and includes financial covenants, including minimum revenue and liquidity thresholds.
- Working capital was $179.5 million. The reserve for veterinary invoices was $43.7 million, a material estimate subject to actuarial and claims-development assumptions.
- APIC held statutory capital and surplus of $162.2 million, above the $142.4 million required threshold. The company also maintained a Canadian trust account of CAD $10.4 million.
Material changes versus the prior comparable period
- Revenue growth remained strong, but the mix shifted toward the lower-margin other business segment, which grew to 34% of revenue from 29%.
- Veterinary invoice expense increased faster than subscription revenue, causing subscription cost of revenue to rise to 83% from 82% of segment revenue.
- The company remained unprofitable, with net loss increasing to $44.7 million from $35.5 million and accumulated deficit reaching $171.6 million.
- Operating cash flow turned negative, while the company added substantial floating-rate debt to support liquidity, capital requirements, and growth.
- Two European acquisitions were completed: Smart Paws GmbH for approximately $2.8 million and PetExpert for approximately $12.3 million in net cash. Their consolidated contribution was immaterial in 2022.
- The company repurchased 95,021 shares for approximately $5.8 million and did not declare dividends.
- Comprehensive loss was $54.1 million, including $9.4 million of unfavorable foreign-currency translation and unrealized investment impacts.
Guidance, outlook, management commentary, and risks
The filing does not provide a clear quantified FY2023 revenue, earnings, or cash-flow guidance. Management expects to continue investing in member acquisition, retention, veterinary invoice automation, technology, new products, international expansion, and additional distribution channels. Management stated that available cash, investments, and credit availability were sufficient to fund operations and capital requirements for the next 12 months, while noting that additional financing may be pursued.
- Management expects the other business segment to begin rolling off a portion of its business in 2023 to redeploy capital, but the timing and extent are not controlled by the company and could cause volatility.
- Growth and profitability depend on member acquisition, retention, pricing approvals, veterinary relationships, and the company’s ability to control veterinary invoice costs.
- Veterinary invoice reserves are a critical accounting estimate; actual claim frequency, severity, utilization, and processing costs may differ materially from estimates.
- The company retains substantially all insurance risk and has not transferred risk to third-party reinsurers for its principal insurance operations.
- Insurance regulation may constrain capital deployment, pricing changes, dividends, and expansion. APIC had three IRIS ratios outside the usual range, although the filing states that this is not itself a failing result.
- Competition, inflation, recessionary conditions, higher interest rates, foreign-exchange movements, cybersecurity incidents, privacy issues, technology failures, regulatory proceedings, and litigation could adversely affect results.
- The company has incurred significant cumulative losses and may not achieve or maintain profitability. U.S. federal net operating loss carryforwards were approximately $258.9 million before tax-effected presentation, subject to limitation and expiration beginning in 2026.
Important facts investors should verify
- Whether subscription gross margin and veterinary invoice expense improve or continue to deteriorate.
- Whether the other business segment roll-off affects revenue, margins, capital requirements, or customer concentration; one general agent sourced premiums exceeding 10% of total revenue.
- Whether member growth, retention, lifetime value, and pet acquisition cost support a credible path to profitability.
- Operating cash flow, liquidity, debt repayment requirements, floating-rate interest expense, and compliance with credit-facility covenants.
- Adequacy of the $43.7 million veterinary invoice reserve and the sensitivity of results to claims development and veterinary-cost inflation.
- Maintenance of APIC’s required statutory surplus and the availability of cash held in regulated insurance subsidiaries and trusts.
- Integration and performance of the Smart Paws and PetExpert acquisitions and the economics of international expansion.
- The filing’s audited financial statements and internal-control reports, which received unqualified opinions from Ernst & Young LLP.